Drug Combination Details
| General Information of the Combination (ID: C03351) | |||||
|---|---|---|---|---|---|
| Name | Gamma tocotrienol NP Info | + | GW9662 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HPGDS | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-231 | Breast cancer | Homo sapiens | ||||
| Neoplastic +SA cells derived from a mammary adenocarcinoma | Mammary Adenocarcinoma | Homo sapiens | ||||
| Experimental
Result(s) |
Combined Gamma -tocotrienol and PPAR Gamma antagonists treatment in PPAR Gamma negative/silenced breast cancer cells are mediated through PPAR Gamma -independent mechanisms that are associated with a downregulation in COX-2, PGDS, and PGD2 synthesis. | |||||
